(1Z,3Z)-2-ethylpenta-1,3-diene-1-thiol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醇
• 英文名称: (1Z,3Z)-2-ethylpenta-1,3-diene-1-thiol
• 化学式: C₇H₁₂S
• 分子量: 128.24
• InChiKey: LUSSHBLMUCUOGQ-VKLRWAGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
  申请人：Goldstein David Michael

  公开号：US20140221398A1

  公开（公告）日：2014-08-07

  The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

  本公开提供化合物和药学上可接受的盐，这些化合物是酪氨酸激酶抑制剂，特别是BLK、BMX、EGFR、HER2、HER4、ITK、Jak3、TEC、Btk和TXK，因此可用于治疗通过抑制酪氨酸激酶治疗的疾病，例如癌症和炎症性疾病，如关节炎等。此外，还提供了含有这些化合物和药学上可接受的盐的药物组合物和制备这些化合物和药学上可接受的盐的过程。
• Catalytic C-H Bond Activation
  申请人：Georgetown University

  公开号：US20150321982A1

  公开（公告）日：2015-11-12

  Disclosed is a method for the transition metal-mediated oxidation of C—H bonds to form C—O or C—S bonds. The methods are useful for the formation of ethers (R—OR′) from alcohols, R′OH, and sp 3 -hybridized C—H bonds in substrates, R—H. Aryl or heteroaryl acetates may also be used for C—H to C-OAr bond formation. The methods are also useful in the preparation of C—S bonds from acetyl-protected thiols, MeC(O)SR, and disulfides, RSSR. Advantageously, the methods minimize reaction steps, the handling of oxidized intermediates, and environmental impact.

  本发明公开了一种过渡金属介导的氧化C-H键形成C-O或C-S键的方法。该方法可用于从醇，R'OH和底物中的sp3杂化C-H键形成醚（R-OR'）。芳基或杂环基乙酸酯也可用于C-H到C-OAr键的形成。该方法还可用于从乙酰保护的硫醇，MeC（O）SR和二硫化物，RSSR中制备C-S键。该方法具有反应步骤少，处理氧化中间体少，对环境的影响小的优点。
• TYROSINE KINASE INHIBITORS
  申请人：Principia Biopharma Inc.

  公开号：US20150353557A1

  公开（公告）日：2015-12-10

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供了化合物及其药学上可接受的盐，它们是酪氨酸激酶抑制剂，特别是BLK、BMX、EGFR、HER2、HER4、ITK、TEC、BTK和TXK，因此可用于治疗通过抑制酪氨酸激酶治疗的疾病，如癌症和炎症性疾病，如关节炎等。还提供了含有这些化合物及其药学上可接受的盐的制药组合物和制备这些化合物及其药学上可接受的盐的过程。
• US8895781B2
  申请人：——

  公开号：US8895781B2

  公开（公告）日：2014-11-25
• US8946241B2
  申请人：——

  公开号：US8946241B2

  公开（公告）日：2015-02-03